Read More Pharma Industry News Why Iovance Biotherapeutics faces a class action lawsuit after a 45% stock crash Iovance faces a class action lawsuit after cutting 2025 revenue guidance by 40%. Learn what triggered the stock’s 45% drop and how investors can file claims. byPallavi MadhirajuMay 31, 2025